Diagnostic and Prognostic Value of MiR-451 Expression in Colorectal Cancer: A Meta-Analysis

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2024 Jun 25

PMID 38918650

Authors

Nasrin Amiri-Dashatan

Mehdi Koushki

Nayeb Ali Ahmadi

Hesameddin Ahmadi

Mostafa Rezaei Tavirani

Affiliations

Soon will be listed here.

Abstract

Background: The miR-451 has been reported to play an important role in colorectal cancer (CRC) pathogenesis and can be a pivotal diagnosis biomarker of CRC. Given the contradictions in the diagnosis value of the miR-451 in patients with CRC, deciphering the diagnostic/prognostic role of this miRNA in CRC will support the identification of a novel therapeutic target for CRC. Therefore, in the present meta-analysis, we evaluated the diagnostic value of miR-451 in CRC patients.

Materials And Methods: The electronic databases of Embase, PubMed, ISI Web of Science, and Scopus systematically searched for relevant studies. The odds ratio (OR) with a 95% confidence interval (CI) was calculated to evaluate the association between miR-451 family expression and diagnosis of colorectal cancer. The parameters including sensitivity, specificity, and area under the curve (AUC) were obtained. The quality of evidence was evaluated using the Newcastle-Ottava Scale (NOS).

Results: This study involved 510 patients (45% female and 55% male) with CRC. The pooled analysis of the studies showed a significant association between low expression levels of miR-451 in patients with CRC (OR = 7.59; 95% CI 2.39 - 24.07; p = 0.001). The overall sensitivity and specificity were 0.95 (0.61 - 1) and 0.83 (0.43 - 0.99), respectively. The pooled AUC was 0.97 (0.88 - 1; p < 0.006). Results showed if the pre-test probability is 50% for a patient, the post-test probability will be 85%. The indices demonstrated the high potency of miR-451 as a diagnostic biomarker in patients with CRC. No publication bias was observed using the Begg's (p=0.85) and Egger's tests (p=0.45).

Conclusion: A strong relationship between the low expression levels of miR-451 and CRC progression was observed. This finding suggests the miR-451 family may be helpful as a potential biomarker for the earlier diagnosis of colorectal cancer.

References

Amiri-Dashatan N, Koushki M, Naghi-Zadeh M, Razzaghi M, Mohaghegh Shalmani H . Prognostic value of microRNA-125a/b family in patients with gastric cancer: a meta-analysis. Gastroenterol Hepatol Bed Bench. 2022; 14(Suppl1):S1-S9. PMC: 8817754. View

Kim T, Croce C . MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Exp Mol Med. 2023; 55(7):1314-1321. PMC: 10394030. DOI: 10.1038/s12276-023-01050-9. View

Zhu J, Xu Y, Liu S, Qiao L, Sun J, Zhao Q . MicroRNAs Associated With Colon Cancer: New Potential Prognostic Markers and Targets for Therapy. Front Bioeng Biotechnol. 2020; 8:176. PMC: 7075808. DOI: 10.3389/fbioe.2020.00176. View

Ruhl R, Rana S, Kelley K, Espinosa-Diez C, Hudson C, Lanciault C . microRNA-451a regulates colorectal cancer proliferation in response to radiation. BMC Cancer. 2018; 18(1):517. PMC: 5932766. DOI: 10.1186/s12885-018-4370-1. View

Melo S, Esteller M . Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett. 2010; 585(13):2087-99. DOI: 10.1016/j.febslet.2010.08.009. View

Selcuklu S, Donoghue M, Spillane C . miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans. 2009; 37(Pt 4):918-25. DOI: 10.1042/BST0370918. View

Liu D, Liu C, Wang X, Ingvarsson S, Chen H . MicroRNA-451 suppresses tumor cell growth by down-regulating IL6R gene expression. Cancer Epidemiol. 2014; 38(1):85-92. DOI: 10.1016/j.canep.2013.12.005. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Bai H, Wu S . miR-451: A Novel Biomarker and Potential Therapeutic Target for Cancer. Onco Targets Ther. 2020; 12:11069-11082. PMC: 6924581. DOI: 10.2147/OTT.S230963. View

10.

Kim J, Yao F, Xiao Z, Sun Y, Ma L . MicroRNAs and metastasis: small RNAs play big roles. Cancer Metastasis Rev. 2017; 37(1):5-15. PMC: 5803344. DOI: 10.1007/s10555-017-9712-y. View

11.

Sun Y, Liu Y, Cogdell D, Calin G, Sun B, Kopetz S . Examining plasma microRNA markers for colorectal cancer at different stages. Oncotarget. 2016; 7(10):11434-49. PMC: 4905484. DOI: 10.18632/oncotarget.7196. View

12.

Phua L, Chue X, Koh P, Cheah P, Chan E, Ho H . Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians. Oncol Rep. 2014; 32(1):97-104. DOI: 10.3892/or.2014.3193. View

13.

Mamoori A, Wahab R, Vider J, Gopalan V, Lam A . The tumour suppressor effects and regulation of cancer stem cells by macrophage migration inhibitory factor targeted miR-451 in colon cancer. Gene. 2019; 697:165-174. DOI: 10.1016/j.gene.2019.02.046. View

14.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

15.

Rasmussen M, Jensen N, Tarpgaard L, Qvortrup C, Romer M, Stenvang J . High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol. 2013; 7(3):637-46. PMC: 5528477. DOI: 10.1016/j.molonc.2013.02.016. View

16.

Koushki M, Amiri Dash Atan N, Omidi-Ardali H, Rezaei Tavirani M . Assessment of Correlation Between miR-210 Expression and Pre-Eclampsia Risk: A Meta-Analysis. Rep Biochem Mol Biol. 2018; 7(1):94-101. PMC: 6175589. View

17.

Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M . MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 2011; 29(11):1661-71. DOI: 10.1002/stem.741. View

18.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

19.

Hamza T, Arends L, van Houwelingen H, Stijnen T . Multivariate random effects meta-analysis of diagnostic tests with multiple thresholds. BMC Med Res Methodol. 2009; 9:73. PMC: 2787531. DOI: 10.1186/1471-2288-9-73. View

20.

Sado A, Batool W, Ahmed A, Zafar S, Patel S, Mohan A . Role of microRNA in colorectal carcinoma (CRC): a narrative review. Ann Med Surg (Lond). 2024; 86(1):308-318. PMC: 10783342. DOI: 10.1097/MS9.0000000000001494. View